Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: A 12-week study

Summary Background Indacaterol is a novel, inhaled once-daily ultra-long-acting β2 -agonist for the treatment of COPD. Methods This 12-week randomised, parallel-group study compared the efficacy of indacaterol 150 μg once-daily to salmeterol 50 μg twice-daily in patients with moderate-to-severe COPD...

Full description

Saved in:
Bibliographic Details
Published in:Respiratory medicine 2011-05, Vol.105 (5), p.719-726
Main Authors: Korn, Stephanie, Kerwin, Edward, Atis, Sibel, Amos, Carolynn, Owen, Roger, Lassen, Cheryl
Format: Article
Language:English
Subjects:
Albuterol - administration & dosage
Albuterol - analogs & derivatives
beta2-agonist
Biological and medical sciences
Bronchodilator
Bronchodilator Agents - administration & dosage
Chronic obstructive pulmonary disease, asthma
Confidence intervals
COPD
Diabetes
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Drug therapy
Female
Forced Expiratory Volume - drug effects
Forced Expiratory Volume - physiology
Humans
Indacaterol
Indans - administration & dosage
Male
Medical sciences
Middle Aged
Pharmaceutical industry
Pneumology
Pulmonary Disease, Chronic Obstructive - drug therapy
Pulmonary Disease, Chronic Obstructive - physiopathology
Pulmonary/Respiratory
Quinolones - administration & dosage
Respiratory Function Tests - methods
Salmeterol
Salmeterol Xinafoate
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Indacaterol is a novel, inhaled once-daily ultra-long-acting β2 -agonist for the treatment of COPD. Methods This 12-week randomised, parallel-group study compared the efficacy of indacaterol 150 μg once-daily to salmeterol 50 μg twice-daily in patients with moderate-to-severe COPD. Assessments included FEV1 standardised area under curve (AUC) from 5 min to 11 h 45 min at Week 12 (primary endpoint), 24-h trough FEV1 (mean of 23 h 10 min and 23 h 45 min post-dose) at Week 12 (key secondary endpoint), FEV1 and FVC measured over 24-h, transition dyspnoea index (TDI) and rescue medication use. Results Of 1123 patients randomised 92.1% completed. Mean ± SD age was 62.8 ± 8.78 years, post-bronchodilator FEV1 51.8 ± 12.32% predicted, FEV1 /FVC 50.6 ± 9.54%. At Week 12, FEV1 AUC5 min–11 h 45 min for indacaterol was statistically superior ( p  
ISSN:0954-6111
1532-3064
DOI:10.1016/j.rmed.2011.02.008